Recordati: Pipeline, Products, Performance, Potential

Pharmaceutical company intelligence reports from Espicom provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

Recordati markets products in the following fields: Cardiovascular, Central Nervous System,Gastroenterology/Urology; Respiratory and Anti-infectives. Future research efforts will focus on fixed combinations in the treatment of hypertension and the development of therapies for micturition disorders.

In December 2007, Recordati acquired Orphan Europe broadening the group's therapeutic areas to include pharmaceuticals for rare and orphan diseases. Orphan's candidates target niche markets in neonatal, paediatric and metabolic disorders. These are new fields for Recordati and will diversify its product portfolio.

Recordati believes its extended European coverage, consolidated expertise in concluding effective collaborations with third parties and its competence and experience in dealing with European regulatory affairs authorities, make the company competitive in obtaining new product licenses for the European markets, even against the larger pharmaceutical companies.

Recordati is also making efforts to maximise the potential of its in-house developed products.